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 51 
Summary 52 
 53 
MHC molecules are found in all jawed vertebrates, and are known to present peptides 54 
to T lymphocytes. In mammals, peptides can hang out either end of the peptide-binding 55 
groove of classical class II molecules, whereas the N- and C-termini of peptides are 56 
typically tightly bound to specific pockets in classical class I molecules. The chicken 57 
MHC, like many non-mammalian vertebrates, has a single dominantly-expressed 58 
classical class I molecule, encoded by the BF2 locus. We determined the structures of 59 
BF2*1201 bound to two peptides, and found that the C-terminus of one peptide hangs 60 
outside of the groove, with a conformation much like the peptides bound to class II 61 
molecules. We found that BF2*1201 binds many peptides that hang out of the groove at 62 
the C-terminus, and the sequences and structures of this MHC I allele was determined 63 
to investigate the basis for this phenomenon. The classical class I molecules of 64 
mammals have a nearly invariant Tyr (Tyr84 in humans) that coordinates the peptide 65 
C-terminus, but all classical class I molecules outside of mammals have an Arg in that 66 
position, in common with mammalian class II molecules. We find that this invariant 67 
Arg residue switches conformation to allow peptides to hang out of the groove of 68 
BF2*1201, suggesting that this phenomenon is common in chickens and other 69 
non-mammalian vertebrates, perhaps allowing the single dominantly-expressed class I 70 
molecule to bind a larger repertoire of peptides.  71 
 72 
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Introduction 73 
 74 
The major histocompatibility complex (MHC) is a genetic region found in all 75 
vertebrates, encoding class I and class II molecules with crucial roles in immune 76 
responses (1, 2). The classical molecules are highly polymorphic, specifically binding 77 
certain peptides depending on the allele, and then presenting them for recognition by T 78 
lymphocytes. Although there are exceptions and other important mechanisms, broadly 79 
speaking the classical class I molecules present peptides derived from the cytoplasm 80 
and nucleus (where viruses and a few bacteria replicate) to CD8-bearing cytotoxic T 81 
lymphocytes (CTLs), while classical class II molecules present peptides derived from 82 
intracellular vesicles and the extracellular space (where bacteria, parasites and fungus 83 
are found) to CD4-bearing regulatory and effector T cells. In addition to the adaptive 84 
immune system, the classical class I molecules are recognized by natural killer (NK) 85 
cells as part of the innate immune system (2, 3). 86 
 87 
The groove of class II molecules is open on either end, so that the peptides can vary in 88 
length, with the amino acids outside the nonamer core hanging out the ends (3, 4). In 89 
contrast, the groove of classical class I molecules are blocked at each end, so that 90 
peptides longer than octamers bulge up in the middle. The peptides bound to class I 91 
molecules are generally short (8-10mers, although much longer peptides have been 92 
described) with free N- and C-termini (3, 5, 6). The free N- and C-termini are 93 
co-ordinated by eight invariant residues, including Tyr84 that binds the C-terminal 94 
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carboxyl group (7-10). Until recently, no extensions at the N- or C-termini had been 95 
reported, but a C-terminal extension was reported to reduce binding affinity by ten-fold 96 
(11). 97 
 98 
In addition to the conserved binding at the N- and C-termini, specificity of binding to 99 
class I molecules is largely determined by anchor residues that generally have one or a 100 
few amino acids with similar chemical characteristics, resulting in a characteristic motif 101 
for each class I molecule (5). Anchor residues have been found at a number of positions 102 
(along with other positions that have preferred residues, often referred to as secondary 103 
anchors), but most typically mammalian class I molecules have anchor residues at 104 
peptide position 2 (P2) and at the C-terminal position (PΩ), which fit into so-called 105 
pockets B and F, respectively (5). One well-studied exception is the mouse class I 106 
molecule H-2Kb, which has anchor residues at PΩ, and P5 for octomers (P6 for 107 
nonamers), with the particular amino acid found at P2 reported to co-vary with the 108 
amino acid at P5(P6) (9, 12, 13).  109 
 110 
Compared to mammals, the chicken MHC is simple and compact, with only the class I 111 
molecule encoded by the BF2 locus expressed at a high level (14-16). The reason for 112 
this dominantly-expressed class I molecule is the fact that the chicken MHC, in stark 113 
contrast to the MHC of typical mammals, suffers very little recombination and encodes 114 
polymorphic peptide-loading complex (PLC) molecules, including transporters 115 
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associated with antigen processing (TAPs) and tapasin, which for each haplotype 116 
co-evolve with the particular BF2 allele present (17-20).  117 
 118 
In comparison to the MHC of typical mammals, the chicken MHC (the BF-BL region 119 
or the B locus in which it is located) determines striking genetic associations with 120 
resistance or susceptibility to infectious diseases, many of which are of economic 121 
importance for the global poultry industry (21, 22). The multigene family of class I 122 
molecules expressed by typical mammals means that there are multiple chances to 123 
present a protective peptide, so most MHC haplotypes confer more-or-less resistance to 124 
most pathogens, which reads out as weak genetic associations. In contrast, the single 125 
dominantly-expressed class I molecule of a chicken MHC haplotype will either find a 126 
protective peptide or not, so a particular MHC haplotype can determine life or death for 127 
a chicken, which reads out as strong genetic associations (23, 24). Thus, the peptide 128 
motif for the dominantly-expressed class I molecule is particularly important. These 129 
motifs range from those much more promiscuous (BF2*0201, 1401 and 2101) to those 130 
more fastidious (BF2*0401, 1201, 1501 and 1901) than those reported for humans and 131 
mice (15, 25-27). The peptides determined for the fastidious class I molecules have 132 
been largely octamers with three anchor residues, with a structure reported for 133 
BF2*0401(26).  134 
 135 
The first chicken class I gene identified encodes the fastidious BF2*1201 molecule 136 
(now officially designated BF2*012:01), for which the peptide motif was reported 137 
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generally to be octamers with Val or Ile at position 5, and Val at position 8 (VI5-V8) 138 
(15, 28, 29). This original motif as well as less stringent versions were used for 139 
prediction and testing of T cell epitopes for a variety of chicken pathogens and 140 
vaccines, including Rous sarcoma virus (RSV), infectious bursal disease virus (IBDV) 141 
and avian influenza virus (AIV) (15, 30, 31). In the first and most complete analysis, 13 142 
peptides were predicted for the v-src gene of RSV Prague strain C, for which chickens 143 
of the B12 haplotype were resistant. Of these putative T cell epitopes, only three were 144 
found to increase the amount of class I molecules stabilized at the cell surface, and 145 
immunization with the strongest binding peptide was found to reduce incipient tumors 146 
(15, 32). Similarly, peptides were predicted for an IBDV molecular vaccine that 147 
correlated with protection (30), and for AIV infection that elicted interferon-γ 148 
production by CD8 T cells (31). Thus, the peptide motif for BF2*1201 is of interest for 149 
explaining disease resistance and vaccine responses.  150 
  151 
Two additional mysteries arise from the original study of BF2*1201(15). First, no 152 
obvious similarities were found for the amino acids at P2, and no evidence for the kind 153 
of co-variation reported for H-2Kb in mouse was noted. Thus, the role of P2 residues 154 
binding into pocket B remains unknown. Second, there was one peptide eluted from 155 
B12 cells that was a nonamer with a Val at P8 and a Thr at P9. One possibility was that 156 
the methyl group of the Thr binds into pocket F like a methyl group of Val in other 157 
peptides, but another possibility was that Val8 fits into pocket F and Thr9 is outside the 158 
groove. Several recent studies indicate that the C-terminal-extended peptides can bind 159 
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to some mammalian MHC I alleles upon significant conformational shifts, including 160 
the Tyr84 (49, 50, 61). Interestingly, the sequences of chicken class I molecules have 161 
seven of the eight invariant residues that co-ordinate the N- and C-termini of the 162 
peptides, but the equivalent of the Tyr84 is always an arginine in chickens, and indeed 163 
in virtually all non-mammalian vertebrates (33, 34). Moreover, for class II molecules 164 
that allow the peptides to hang out the end of the groove, the equivalent position is also 165 
an arginine (33, 34). Thus, the question arises whether this arginine might allow 166 
peptides to hang out of the C-terminal end of the peptide-binding groove. 167 
 168 
The salient features of the chicken MHC and class I molecules are found in many if not 169 
most non-mammalian vertebrates (35, 36). Thus, the chicken provides a model for 170 
these other vertebrates, some of which are of economic or conservation interest. In 171 
addition, there are there several mysteries about BF2*1201, so we decided to examine 172 
the structure and peptides further.  173 
174 
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 175 
Materials and Methods 176 
 177 
Peptide synthesis and preparation of expression constructs. Potential chicken MHC I 178 
BF2*1201-binding peptides and their substitutions (Table 1, TableS1) were 179 
synthesized and purified by reverse-phase high-performance liquid chromatography 180 
(HPLC) (SciLight Biotechnology, Beijing). The peptide purity was determined to be 181 
>95% by analytical HPLC and mass spectrometry. The peptides were stored at -80°C as 182 
freeze-dried powders and were dissolved in dimethyl sulfoxide (DMSO) before use. 183 
The cDNAs for BF2*1201 (GenBank: Z54329.1) were synthesized (Genewiz Inc, 184 
Beijing). The amplified products expressing the extracellular domain (residues 1–270) 185 
of BF2*1201 were cloned into a pET21a vector (Novagen) and transformed into 186 
Escherichia coli strain BL21(DE3). The expression plasmid for chicken β2m 187 
(expressing residues 1-98) was constructed previously in our laboratory (37).  188 
Refolding and purification of BF2*1201. Dilution-renaturation and purification of 189 
MHC I assembled with peptides were performed as described previously (37). Firstly, 1 190 
mL dissolved chβ2m inclusion bodies was dropped slowly to 500 mL refolding buffer 191 
(100 mM Tris-HCl pH 8.0, 2 mM EDTA, 400 mM L-Arg, 0.5 mM oxidized 192 
glutathione, 5 mM reduced glutathione) and incubated at 4℃for 0.5 h. Subsequently, 5 193 
mg peptide dissolved in dimethyl sulfoxide (DMSO) was added to the solution. Half an 194 
hour later, 3 mL BF2*1201 heavy chain inclusion bodies were added to the solution 195 
drop by drop. After incubation for 8 h, the soluble portion was concentrated and 196 
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purified by chromatography on a Superdex 200 16/60 HiLoad (GE Healthcare) 197 
size-exclusion column. For the crystallization, the protein was further purified by 198 
Resource Q (GE Healthcare) anion-exchange chromatography. 199 
Crystallization, data collection, and processing. Crystallization of was performed using 200 
the sitting drop vapor diffusion technique. Plates were incubated at 291 K and assessed 201 
for crystal growth after 1-2 weeks. BF2*1201/S1 crystals were observed in  0.1M 202 
BICINE pH 8.5,20% w/v PEG 10,000 at a concentration of 16mg/mL. Single crystals 203 
of BF2*1201/A6 were grown in10%v/v polyethylene glycol 200, 0.1M BIS-Tris 204 
propane pH 9.0, 18%w/V, Polyethylene glycol 8,000 at a protein concentration of 16 205 
mg/mL. Diffraction data for both crystals were collected at 100 K at the SSRF 206 
BEAMLINE BL17U, Shanghai, China at a wavelength of 0.97914 Å and 0.97539 Å, 207 
respectively. In both cases, the crystals were first soaked in reservoir solution 208 
containing 15% glycerol as a cryoprotectant for several seconds and then flash-cooled 209 
in a stream of gaseous nitrogen at 100 K. The collected intensities were subsequently 210 
processed and scaled using the DENZO program and the HKL2000 software package 211 
(HKL Research)(38).  212 
 213 
Structure determination and analysis. The structure of BF2*1201/A6 was determined 214 
by molecular replacement using BF2*0401/IE8 (Protein Data Bank [PDB] code 4E0R) 215 
as a search model in the Crystallography & NMR System (CNS) program (39). Clear 216 
solutions in both the rotation and translation functions correspond to two molecules in 217 
one asymmetric unit. The residues that were different in BF2*1201 and the search 218 
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model BF2*0401/IE8 were manually rebuilt in the COOT program under the guidance 219 
of Fo-Fc and 2Fo-Fc electron density maps (40). Subsequently, we refined the initial 220 
rigid body and performed a series of restrained translation, libration, and screw-motion 221 
(TLS) refinements with the REFMAC5 program (41). Additional rounds of refinement 222 
were performed using the phenix refine program implemented in the PHENIX package 223 
with isotropic ADP refinement and bulk solvent modeling (42). We assessed the 224 
stereochemical quality of the final model with the PROCHECK program (43). The 225 
structure of BF2*1201/S1 was determined by using the final model of BF2*1201/A6 226 
through molecular replacement, with four molecules present in one asymmetric unit. 227 
The same refinement steps were performed to generate the final model of 228 
BF2*1201/SRC. Crystallographic statistics for the final models of the two complexes 229 
are given in Table S1. The molecular models and the electron density-related figures 230 
were generated using PyMOL (http://www.pymol.org/). The sequence alignment was 231 
generated with Clustal X (44) and ESPript (45). 232 
 233 
Thermostability measurements using circular dichroism (CD). To evaluate the 234 
thermostability of MHC I/ peptide complexes, we used the CD spectroscopy method as 235 
previously described (46). All complexes were prepared as described above and diluted 236 
to 200 μg/mL in 20 mM Tris-HCl (pH 8.0) and 50 mM NaCl. CD spectra at 218 nm 237 
were measured on a Chirascan spectrometer (Applied Photophysics) using a 238 
thermostatically controlled cuvette at temperature intervals of 0.2°C and a rate of 239 
1°C/min between 20-90°C. The proportion of denatured protein was calculated from 240 
13 
 
the mean residue ellipticity (u) using the standard method: fraction unfolded (%) = (θ241 
－θa)/(θa－θb), where θa and θb are the mean residue ellipticity values in the fully 242 
folded and fully unfolded states, respectively. The denaturation curves were generated 243 
by nonlinear fitting with OriginPro 8.0 (OriginLab). The midpoint transition 244 
temperature (Tm) was calculated by fitting data to the denaturation curves and using 245 
inflexion-determining derivatives. 246 
 247 
Accession numbers. Atomic coordinates and structure factors have been deposited in 248 
the Protein Data Bank (http://www.rcsb.org) under accession codes 5YMW for 249 
BF2*1201/S1 and 5YMV for BF2*1201/A6. 250 
251 
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 252 
Results 253 
 254 
Immunogenic peptides from pathogens based on the motif (V/I)5-V8 will allow 255 
refolding of BF2*1201 256 
Peptides eluted from class I molecules on B12 cells suggested a motif of (V/I)5-V8, 257 
which was consistent with a structural model of the BF2*1201 molecule (15). This 258 
motif (relaxed to allow nonamers as well) predicted many peptides from the sequence 259 
of RSV Prague strain C, and three peptides from the v-src gene gave a detectable signal 260 
in a cell-binding assay, which here we call B12-P1 (GENLVCKV, with putative anchor 261 
residues underlined), B12-P2 (LAGGVTTFV) and B12-S1 (LPACVLEV). 262 
Immunization with B12-S1 protected B12 chickens from tumors after RSV infection 263 
(32). The same motif (relaxed to allow nonamers as well as related hydrophobic amino 264 
acids) was used to predict peptides from AIV sequences (A/chicken/Italy/1067/99), 265 
from which we chose to examine five peptides, which here we call B12-A1 266 
(NATEIRASV), B12-A6 (AVKGVGTMV) and B12-A11 (EDLRVSSFI) from the 267 
nucleoprotein, and B12-F1 (VETYVLSI) and B12-F7 (KTRPILSPL) from matrix 268 
protein 1. These peptides were shown to stimulate T cells from infected chickens to 269 
produce interferon-γ (31). However, no careful molecular assay has been used to 270 
examine the binding of these peptides to the BF2*1201 molecule (Table I). 271 
 272 
Using a refolding assay (renaturation followed by size exclusion chromatography) as in 273 
previous work (25, 26), we found that six peptides supported refolding to give a stable 274 
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monomer (peptide, heavy chain and β2m) of the BF2*1201 molecule (Fig. 1). Five 275 
peptides with the canonical motif ((V/I5)-V8 for octamers, (V/I)5-V9 for nonamers) 276 
gave good yields, one octamer with a non-canonical residue in the PΩ position (V5-I8) 277 
gave a lesser yield, and two nonamers with non-canonical Ile and Leu residues at PΩ 278 
gave no properly folded protein. The results are clear for these few peptides, and can be 279 
interpreted to suggest that octamers are the most stable length and therefore may 280 
tolerate non-canonical residues in some anchor positions. This interpretation is 281 
consistent with the self peptides, which were octamers with (V/I)5-V8, except one with 282 
V5-L8 and one nonamer.  283 
 284 
For the six peptides that supported refolding, several amino acids were found at P2: two 285 
with Ala, one with Val, one with Pro, and two with Glu (Table I). This result is 286 
consistent with the self peptides eluted from B12 cells, for which there were two with 287 
Ala, two with Gln and one with Thr (15). Both for self peptides and the six confirmed 288 
predicted peptides, there was no evidence for one or a few amino acids with similar 289 
chemical properties at P2, nor any evidence for co-variation of position P2 with 290 
position P5 as is found in H-2Kb. 291 
 292 
 293 
Two structures of BF2*1201 with pathogen peptides show three positions that anchor 294 
the peptide 295 
 296 
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The fact that a variety of amino acids, ranging from small hydrophobic and small polar 297 
to large polar and negatively-charged residues, are found at P2 of BF2*1201-binding 298 
peptides leaves open the question whether P2 is an anchor residue in the classic sense. 299 
In order to answer this question, and to further understand structure-function 300 
relationships, we determined the crystal structures of BF2*1201 in complex with the 301 
RSV-derived peptide S1 and the AIV-derived peptide A6 (Table II).  302 
 303 
Overall, the structure of BF2*1201 has the common characteristics of other classical 304 
class I molecules: the extracellular region of the heavy chain folds into three different 305 
domains (Fig. S1A), the α1 and α2 domains form a typical peptide binding groove 306 
which contains two α1-helices and eight β-sheets, and the α3 domain and β2m display 307 
typical immunoglobulin domains and underpin the peptide binding domain. The 308 
superposition of BF2*1201 onto previously determined BF2 alleles from the B2, B4, 309 
B14 and B21 haplotypes showed root mean square deviations (RMSDs) of 0.55 to 0.71 310 
Å (Fig. S1B). The most distinct differences between BF2*1201 and the other alleles are 311 
located in the loop between β1 and β2 strands of the α2 domain and the β1-β2 loop in 312 
the α3 domain (Fig. S1B).  313 
 314 
As expected for octamer peptides bound to class I molecules, the peptide S1 and the 315 
first eight amino acids of peptide A6 are flat and low in the peptide-binding groove 316 
(Fig. 2A, B), with the Val5 in both peptides located as deep in the groove as the amino 317 
acids at P2 and P8 (Fig. 2C, D). Compared to the crystal structures of octamer peptides 318 
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bound to various class I molecules from chickens, mice and humans, the Cα atom of the 319 
P5 residues are located 0.84 Å lower than the lowest previously reported (Fig. 3).  320 
 321 
Like the fastidious chicken allele BF2*0401 (now officially designated as 322 
BF2*004:01) (26), BF2*1201 has a narrow groove but in contrast, the BF2*1201 323 
groove is overall hydrophobic as revealed by the vacuum electrostatic surface potential 324 
(Fig. 2E, F). As expected, the amino acids at P5 (Val in both peptides) and P8 (Val in S1 325 
and Met in A6) are anchor residues located in the C and F pockets respectively, but the 326 
amino acids at P2 (Pro in S1 and Val in peptide A6) also act as anchor residues, being 327 
located deep in the B pocket, nestling under the α1 helix. For these peptides, the anchor 328 
residues have relatively small hydrophobic side chains, but larger polar and charged 329 
amino acids like Glu and Gln have also been found at P2 (15). The way in which these 330 
larger side chains are accommodated remains to be determined.  331 
 332 
In order to examine the role of these anchor residues more closely, Gly swaps for the 333 
three positions were tested by refolding assays, and the thermal stability of resulting 334 
monomers was monitored by circular dichroism (CD) spectroscopy (Fig. 4, Table S1). 335 
Substitution of Gly at P8 led to no refolding for either peptide, and Gly at P5 in the AIV 336 
peptide A6 also led to no refolding, whereas Gly at P5 in the RSV peptide S1 supported 337 
refolding although the monomer was significantly less stable than the original peptide. 338 
In contrast, substitution of Gly at P2 in either peptide led to only minor reductions in the 339 
yield of refolded monomers, which had similar stabilities compared to the original 340 
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peptides. So, by these analyses, the P2 anchor of BF2*1201 binding peptides seems 341 
more promiscuous compared to the P5 and P8 anchors.  342 
 343 
 344 
The stability of peptide binding to BF2*1201 is not affected by C-terminal residues 345 
hanging out of the groove  346 
 347 
By far the most common C-terminal anchoring mode, found in nearly every structure of 348 
mammalian class I molecules, is for the side chain of the amino acid at PΩ to insert into 349 
pocket F, and the C-terminal carboxyl group to bind with a hydrogen bond to Thr141 350 
and Tyr84. Examples include the SARS-CoV peptide Mn2 bound to HLA-A*0201 and 351 
the MERS-CoV peptide 37-1 bound to H-2Kd (Fig. 5C-F) (47, 48). A similar mode of 352 
binding is found for the RSV octamer peptide S1 (and all other structures of chicken 353 
class I molecules known), although Tyr84 in mammals is replaced by Arg83 in 354 
chickens (Fig. 5A, B). However, most striking observation from the structures of 355 
BF2*1201 is the fact that the anchor residue for the AIV nonamer peptide A6 is Met8, 356 
with the Val9 (which was expected to be the anchor residue) hanging out over the F 357 
pocket. The peptide bond between Met8 and Val9 makes a hydrogen bond with Thr141, 358 
but the carboxyl group of Val9 makes the hydrogen bond with Arg83, pushing the side 359 
chain of Arg83 away to create a more open conformation (Fig. 5G, H).  360 
 361 
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Recently, two structures of mammalian class I molecules were reported that also have 362 
C-terminal amino acids hanging out of the groove (49, 50): Toxoplasma gondii peptide 363 
FK12 (FVLELEPEWTVK) bound to HLA-A*0201 (Fig. 5I, J; Fig. S2B) and insulin 364 
peptide G9GF (LYLVCGERGF) bound to H-2Kd (Fig. 5K, L; Fig. S2C). In both cases, 365 
a single amino acid at the peptide C-terminus hangs out of the groove and Tyr84 is 366 
shifted away, but in neither case does the amino acid at PΩ interact with Tyr84. We 367 
compared these structures to HLA-A*0201 and H-2Kd bound to peptides with the 368 
common C-terminal anchoring mode, and found that the α-helices were significantly 369 
shifted (Fig. 5N, O), with RMSD of 0.402 Å for HLA-A2 and 0.588 Å for H-2Kd. In 370 
contrast, the α-helices of BF2*1201 with peptide S1 and A6 were not shifted (Fig. 5M), 371 
with the RMSD of 0.225 Å not significantly different from RMSD of 0.201 Å between 372 
the two molecules in the asymmetric unit of the BF2*1201/S1 structure.  373 
 374 
We tested whether a C-terminal residue hanging out of the groove would affect stability 375 
of different MHC molecules. The AIV nonamer peptide A6 (AVKGVGTMV) and the 376 
octamer A6-N8 (AVKGVGTM, the same peptide with the last amino acid deleted) 377 
refolded equally well with BF2*1201, and the resulting monomers were equally stable 378 
(Fig. 6A, B). In contrast, HLA-A*0201 refolded poorly and gave less stable monomers 379 
with the peptide P9-C10 (AIMEKNIVLK) extended one amino acid compared to the 380 
parent peptide P9 (AIMEKNIVL, HLA-A2 restricted peptide from 2009 pandemic 381 
H1N1 influenza virus(51) )(Fig. 6C, D). Similarly, HLA-A*1101 didn’t refold at all 382 
with the peptide P23-C11 (RFSSFIRGKKV) extended one amino acid compared to the 383 
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parent peptide P23 (RFSSFIRGKK, HLA-A11 restricted peptide from 2009 pandemic 384 
H1N1 influenza virus(51)) (Fig. 6E, F). These results for mammals fit well with the 385 
original observation by Wiley and colleagues (11) that a decamer calreticulin peptide 386 
with a single amino acid C-terminal extension bound to HLA-A*0201 has a marked 387 
effect on stability of binding.  388 
 389 
Finally, we tested by refolding the AIV peptide S1 (31) as well as five self peptides 390 
eluted from B12 cells (15), here called P4 – P8, extended by up to three C-terminal 391 
amino acids. All of the extended peptides refolded as well as the parent peptide, 392 
indicating a general ability of BF2*1201 to accommodate peptides with amino acids 393 
that hang out of the groove at the C-terminal end (Table S1). To further investigate 394 
whether the Arg at the C-terminus of the peptide binding groove is responsible for the 395 
intrinsic binding of the C-terminal-extended peptides by BF2*1201, we generated a 396 
R83Y mutant of BF2*1201, which has a Tyr at the position 83. Interestingly, R83Y 397 
mutant of BF2*1201 lost the capacity to bind the AIV nonamer peptide A6 398 
(AVKGVGTMV), indicating a key role for Arg83 in the binding of 399 
C-terminally-extended peptides (Fig. 7). 400 
 401 
 402 
The classical class I molecules of non-mammalian vertebrates generally have Arg83, 403 
which is in the same relative position as an Arg in mammalian class II molecules  404 
 405 
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The first report of the sequence and molecular model of BF2*1901 (now officially 406 
designated BF2*015:02) pointed out that one of the eight invariant residues identified 407 
by Wiley’s group as coordinating the N- and C-termini of the bound peptide, Tyr84 in 408 
humans, is replaced by Arg83 in chickens, and that this position also is an Arg in human 409 
class II molecules (33). As more sequences became available, it became clear that the 410 
classical class I molecules of all placental mammals had Tyr while all known 411 
non-mammalian vertebrates had Arg (34).  412 
 413 
We revisited this analysis by downloading class I sequences from many vertebrates. 414 
We find that, with very few exceptions, the classical class I molecules from almost all 415 
mammals, including marsupials and monotremes (52, 53), have Tyr in the position 416 
equivalent to the human Tyr84, while representative birds, reptiles, amphibians, bony 417 
fish and cartilaginous fish all have Arg (Fig. 8; Table III). Based on our finding with 418 
BF2*1201, the presence of this Arg suggests that class I molecules throughout the 419 
non-mammalian vertebrates have the capacity to accommodate peptides which extend 420 
beyond pocket F.  421 
 422 
The equivalent position in mammalian class II α chain sequences is also an Arg (Fig. 423 
9A, Table III), and structures reveal that this Arg forms a hydrogen bond with the 424 
carbonyl of the peptide bond between the last anchor residue and the first amino acid 425 
that hangs out of the groove (Fig. 9E-I). The conformation of peptides hanging out of 426 
the groove is similar in class II molecules from humans and mice, and to the chicken 427 
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class I molecule BF2*1201 (Fig. 9B, C). However, while the conformation of the Arg 428 
in class II molecules is similar in all structures, the conformation of this Arg in the 429 
chicken class I molecule BF2*1201 is completely different for the overhanging 430 
peptide. For the peptide that is not hanging out of the groove, the conformation of this 431 
Arg in BF2*1201 is very similar to the other structures for chicken class I molecules, 432 
and to canonical conformation of the equivalent Tyr in mammalian class I molecules 433 
(Fig. 9C, D). The presence of this Arg correlates perfectly with the ability of class I and 434 
II molecules to allow peptides to hang out of the groove.  435 
 436 
 437 
The classical class I molecules in chickens have Asp14 which restrains a loop 438 
interaction with β2m  439 
 440 
Examining the sequences of classical class I molecules from a variety of vertebrates 441 
identified another position which is shared among mammals, but is different among 442 
non-mammalian vertebrates. In the position equivalent to Arg14 found in virtually all 443 
mammalian sequences including marsupials and monotremes (52, 53), the sequences 444 
from birds, reptiles and amphibians have an Asp (Fig. S3A). In structures of chicken 445 
class I molecules, Asp14 forms a salt bridge with Lys33 of β2m, resulting in a 446 
consistent conformation of the loop between the first and second β-strands of the α1 447 
domain, and a close interaction with β2m (Fig. S3B, C). In Xenopus, the equivalent 448 
residue in β2m is Arg34 (54), which presumably can make the same interaction. By 449 
23 
 
contrast, the structures of mammalian class I molecules show multiple conformations 450 
of this loop, all of which are farther away from β2m which has various residues at 451 
position 33 including Asp, Gln and His (55). Thus, other important positions besides 452 
Arg83 have changed in the lineage leading to mammals.453 
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 454 
Discussion 455 
 456 
The chicken gene BF2*1201 was the first classical class I gene identified outside of 457 
mammals (28, 29). Among the important findings from the structures of BF2*1201 and 458 
other analyses in this paper are three crucial observations: the identification of P2 as a 459 
promiscuous anchor residue, the role of Arg83 in allowing C-terminal overhangs out of 460 
the peptide-binding groove analogous to class II molecules, and the identification of 461 
Asp14 as an important conserved contact with β2m, distinct from Arg14 in mammalian 462 
class I molecules.   463 
 464 
Most classical class I molecules bind peptides with anchor residues at P2 (fitting into 465 
pocket B) and PΩ (fitting into pocket F), with only a few other configurations. One 466 
well-studied example is the mouse molecule H-2Kb, with obvious anchor residues at 467 
P5/6 and PΩ (9, 12). Subsequent studies showed that there is co-variation between P2 468 
and P5/6, so that the residues at P2 are in fact constrained (13). For BF2*1201, 469 
sequences of both pooled and individual peptides showed mainly octamers with 470 
conserved amino acids at P5 and PΩ, primarily Val and Ile at P5 and Val at P8. A range 471 
of amino acids were found at P2, from the small hydrophobic Ala to the larger acidic 472 
Glu, with no obvious co-variation, so it was not clear whether P2 is an anchor residue.  473 
 474 
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The two structures of BF2*1201 go a long ways towards solving this mystery, with 475 
Val2 and Pro2 clearly nestling under the α1 helix and bound into a canonical pocket B. 476 
Thus, BF2*1201 has three anchor residues much like BF2*0401, but unlike BF2*0401, 477 
P2 in BF2*1201 is promiscuous. Several other chicken class I molecules (BF2*0201, 478 
1401 and 2101) show promiscuous binding of one kind or another, so perhaps this 479 
should not have been a surprise. However, it remains to be determined how larger 480 
residues like Glu and Gln at P2 interact with BF2*1201, perhaps by pocket B 481 
accommodating only the Cβ and Cγ groups of the sidechains. Examination of a much 482 
larger sample of bound peptides, for instance by immunopeptidomics or by assembly 483 
using peptide libraries, might allow the possibility of co-variation to be conclusively 484 
tested.  485 
 486 
Perhaps the most striking observation from the BF2*1201 structures is the role of 487 
Arg83 in allowing peptide overhang out of the C-terminal end of the groove. It was 488 
noted very early on that highly conserved Tyr84 interacts with the peptide C-terminus 489 
in mammals is replaced with Arg in the equivalent position of chickens and all other 490 
non-mammalian vertebrates examined, and that this position is also an Arg in class II 491 
molecules (33, 34). The significance of these observations had not been appreciated 492 
until the two BF2*1201 structures showed that this Arg83 can interact with the 493 
carboxyl group of the C-terminal amino acid in (at least) two conformations, one much 494 
like Tyr84 with the C-terminal amino acid bound into pocket F and the other raised up 495 
allowing the penultimate amino acid to bind into pocket F and the final amino acid to 496 
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extend out of the groove. This finding gives a molecular explanation to the suggestion 497 
that a nonamer peptide eluted from BF2*1201 might hang out of the groove, fits with 498 
unpublished structures for BF2*1401 (P. Chappell, M. Harrison, S. M. Lea and J. 499 
Kaufman, unpublished) and also fits with the motif found for a class I molecule from 500 
commercial chickens (N. Ternette, K. Watson and J. Kaufman, unpublished). 501 
Moreover, this finding can explain the unexpected peptide motif for BF2*0401 502 
transfectants in cells mismatched for MHC haplotype, in which the usual Glu at PΩ was 503 
followed by a hydrophobic residue presumably specified by the alleles of TAP genes 504 
present (56). Different alleles of chicken class I molecules might have different 505 
propensities to allow these overhangs, and additional immunopeptidomics and 506 
structures may help understand this phenomenon further. In any case, it seems likely 507 
that such C-terminal overhangs will be found for all the non-mammalian vertebrates, 508 
allowing class I repertoires to be wider than is generally found in mammals.   509 
 510 
It was shown long ago that a calreticulin peptide with a C-terminal overhang from the 511 
human class I molecule HLA-A2 led to a ten-fold loss of binding affinity, leading to the 512 
expectation that this was not a frequent occurrence (11). However, immunopeptidomics 513 
has identified many longer peptides (57-59). Some of these longer peptides may be due 514 
to extreme bulging in the middle (6, 60). However, other long peptides may involve 515 
C-terminal overhangs, as has been recently reported for two structures with a 516 
conformationally-shifted Tyr84, one with a T. gondii peptide bound to HLA-A*0201 517 
and the other an insulin peptide bound to H-2Kd (49, 50).. These peptide overhangs 518 
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both involve significant shifts in the α-helices and Tyr84, but the conformational shift 519 
of α-helices is not found in the corresponding structures of chicken class I, so the 520 
binding mechanism is completely different from the simple conformational shift of 521 
Arg83 in the chicken class I molecules. The shifted α-helices and Tyr84 to 522 
accommodate C-terminally extended peptides may be more common as revealed by a 523 
recent study in which peptidomics of 54 human class I alleles found C-terminal 524 
extensions for at least eight alleles, including the common HLA-A03:01, HLA-A31:01, 525 
and HLA-A68:01 (61). Moreover, the recent structures of H2-Dd and H2-Db bound to 526 
TAPBPR, the tapasin homolog, revealed the conformational shift of Tyr84 (62,63). In 527 
contrast, the intrinsic Arg83 may suggest that the class I molecules from lower 528 
vertebrates may have less need for either tapasin or TAPBPR during the peptide 529 
loading. 530 
 531 
It has long been believed that class I and class II molecules share a common ancestor, 532 
although it has been controversial whether class I or class II molecules came first 533 
(64-66). The fact that both class II molecules and chicken class I molecules allow 534 
C-terminal peptide overhangs and that this correlates with the presence of a particular 535 
Arg at the same position might be considered to support the idea that an open groove as 536 
found in class II molecules came first. In fact, the conformations of the peptide 537 
overhangs seem very similar (67). However, the conformation of Arg83 in chicken 538 
class I and of the equivalent Arg in class II molecules is not the same; at the moment, 539 
the evolutionary significance of this difference is not clear.  540 
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 541 
Finally, the appearance of Tyr84 in mammals instead of Arg83 in chickens and other 542 
non-mammalian vertebrates is not the only big change in the MHC I. For instance, the 543 
presence of the class III region between the regions encoding the class I and class II 544 
genes, the presence of functionally-monomorphic TAP and tapasin genes, and the 545 
presence of multigene families of well-expressed classical class I molecules all 546 
appeared in the lineage leading to the placental mammals (17, 36). Other changes might 547 
be expected, and one is the loss of Asp14 that is responsible for an intimate interaction 548 
between the α1 domain and β2m. The significance of this change is not clear, but subtle 549 
differences in particular positions can have enormous effects. For instance, a Val to Ile 550 
change within the α3 domain abrogates CD8 binding in HLA*68:01 (68). Similarly, 551 
amino acid polymorphisms in mouse β2m lead to big changes in T cell recognition (69). 552 
Thus, the conserved salt bridge of non-mammalian vertebrates that has been lost in 553 
mammals may have important consequences.  554 
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 813 
Figure legends 814 
 815 
Figure 1. The binding capabilities of peptides to BF2*1201 revealed by in vitro 816 
refold. The refolding efficacy of B12 complex (BF2*1201, Chβ2m and different 817 
epitopes) is evaluated by FPLC Superdex 200 16/60 Hi-Load gel-filtration (GE 818 
Healthcare). The peaks of the complexes with the expected molecular mass of 45 kDa 819 
were eluted at the estimated volume of 83 ml on a Superdex 200 column. The profile is 820 
marked with the approximate positions of the molecular mass standards of 75.0, 43.0 821 
and 29.0 kDa. Peak ① represents the aggregated BF2*1201 heavy chain, peak ② 822 
represents the correctly refolded complex(42 kDa) and peak ③ represents excess 823 
chβ2m.  A. The peptides with a high capability to renature the BF2*1201 complex are 824 
shown. B. The peptides with no or minor capability to renature the BF2*1201 complex 825 
are shown. 826 
 827 
Figure 2. The peptides in the narrow and hydrophobic groove of BF2*1201. (A 828 
and B) Conformations of peptides S1 (A) and A6 (B) in the groove of BF2*1201 are 829 
displayed through the 2Fo-Fc electron density maps contoured at 1.0 σ. The electron 830 
densities are shown as purple mesh viewed in profile with the α2 helix removed for 831 
clarity. (C and D) The P2, P5 and P8 anchors shown in sticks (green for S1 and cyan for 832 
A6) are located in the tangent plane of B, C and F pockets. The similar inserting depth 833 
of P2, P5 and P8 anchors in the pockets are shown with dashed purple lines linking the 834 
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Cα atoms of the residues in these three positions. (E and F) The vacuum electrostatic 835 
surface potential shows the A-F pockets of BF2*1201 labeled with letters in black 836 
circles. The peptides S1 and A6 are shown in green and cyan sticks.  837 
 838 
Figure 3. BF2*1201 presents peptides in lower and flatter conformations 839 
compared with 8-mer peptides in MHC I from other species. S1 and A6 presented 840 
by BF2*1201 are represented by green sticks. All other 8-mer peptides, denoted as 841 
purple sticks, are presented by other mammalian MHC I alleles and chicken MHC I 842 
alleles. The lower position of the middle portion of peptides S1 and A6 presented by 843 
BF2*1201 denoted with blue dashed lines. The structures used are HLA-A*2402 844 
(Protein Data Bank code 4F7T), HLA-B*3508 (3BWA), HLA-B*5101 (4MJI), H-2Kb 845 
(3P4M), and chicken BF2*0401 (4E0R). 846 
 847 
Figure 4. Confirmation of the peptide motif for BF2*1201. (A) Binding of S1 and 848 
its Gly substitutions to BF2*1201 elucidated by in vitro refolding. (B) Capability of A6 849 
and its Gly substitutions to renature BF2*1201. (C and D) Thermostabilities of 850 
BF2*1201 complexes. The thermostabilities of BF2*1201 with peptide S1 and A6 and 851 
their Gly substitutions (S1-P2G, S1-P5G, A6-P2G and A6-P9G) were tested by CD 852 
spectroscopy. The temperature was increased by 1°C/min. The curves for the unfolded 853 
fractions were determined by monitoring the CD value at 218 nm. Shown here are the 854 
data fitted to the denaturation curves using the Origin 8.0 program (OriginLab). The 855 
Tms of different peptides are indicated by the gray line at 50% fraction unfolded. 856 
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 857 
Figure 5. The intrinsic open groove of BF2*1201. A. In the structure of 858 
BF2*1201/S1 (PDB:5YMW), The vacuum electrostatic surface potential shows the 859 
closed groove at the C-terminus of the peptide. B. Detailed interaction of P8-Val of 860 
peptide S1 with residues Arg81 and Thr141 of BF2*1201. C. The closed groove of 861 
HLA-A*0201/Mn2 (PDB:3I6G). D. The interaction of P9-Val of peptide Mn2 with 862 
Tyr83 and Thr141 of HLA-A*0201. E. The closed groove of H-2Kd (PDB: 5GSX). F. 863 
The interaction of P10-Leu with Tyr83 and Thr141 of H-2Kd. G. The opened groove at 864 
the C-terminus of peptide A6 presented by BF2*1201/S1 (PDB: 5YMV). H. The 865 
detailed interaction of hanging out residue P9-Val of peptide A6 with residues Arg81 866 
and Thr141 of BF2*1201. I. The opened groove of HLA-A*0201/UFP(16–27)  (PDB: 867 
5DDH). J. No direct interaction of P12-Lys from peptide UFP(16–27) to Tyr83 can be 868 
observed. K. The opened groove of H-2Kd/G9GF (PDB: 4Z78). L. No direct interaction 869 
of the P10-Phe with residues Tyr81 and Thr141 of H-2Kd. M. The structural 870 
superposition of BF2*1201/S1 and BF2*1201/A6 shows no shift of the α-helices. N. 871 
The structural superposition of HLA-A*0201/Mn2 and HLA-A*0201/UFP(16–27) 872 
shows a conformational shift of the α1-helix of HLA-A*0201. O. The structural 873 
superposition of H-2Kd/142-2 and H-2Kd/G9GF highlights the conformational shift of 874 
the α1-helix of HLA-A*0201.  875 
 876 
Figure 6. The intrinsic open groove enables BF2*1201 to bind to longer peptides 877 
with similar affinity. A. Binding of A6-C8 (AVKGVGTM) and the C-terminal 878 
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extended peptide A6 (AVKGVGTMV)to BF2*1201 elucidated by in vitro refolding. 879 
B. Thermostabilities of BF2*1201 complexed to peptide A6 and A6-C8 examined by 880 
CD spectroscopy. C. Binding of P9 (AIMEKNIVL) and the C-terminal extended 881 
peptide P9-C10 (AIMEKNIVLK) to HLA-A*0201 elucidated by in vitro refolding. D. 882 
Thermostabilities of HLA-A*0201 with peptide P9 and P9-C10 examined by CD 883 
spectroscopy. E. Binding of P23 (RFSSFIRGKK) and the C-terminal extended peptide 884 
P23-C11 (RFSSFIRGKKV) to HLA-A*1101 elucidated by in vitro refolding. F. 885 
Thermostabilities of HLA-A*1101 with peptide P23 were tested by CD spectroscopy; 886 
the C-terminal extended peptide (P23-C11) complexed to HLA-A*1101 was not 887 
available due to the low binding. 888 
 889 
Figure 7.  890 
 891 
Figure 8. Structure-based sequence alignment of BF2*1201 and other MHC I 892 
molecules covering the residue at position 83. Coils indicate α-helices, and black 893 
arrows indicate β-strands. Residues highlighted in red are completely conserved, and 894 
residues in blue boxes are highly (>80%) conserved, with consensus amino acids in red. 895 
Residues at position 83 that are located at the C-terminus of the peptide binding groove 896 
are marked with blue arrow. The residues at position 83 in lower vertebrate and chicken 897 
are shown in yellow. The sequence alignment was generated with Clustal X and 898 
ESPript. 899 
 900 
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Figure 9. The conserved Arg at the C-terminus of the peptide binding groove of 901 
MHC II molecules. A. Sequence alignment of MHC II molecules and other MHC I 902 
molecules for which structures are available covering the residue Arg83 of BF2*1201. 903 
The comparable residues at position 83 of BF2*1201 are marked with blue arrow. The 904 
conserved Arg residues corresponding to Arg83 of BF2*1201 that are located at the 905 
C-terminus of the peptide binding groove of MHC II are shown in yellow. B. Five 906 
representative MHC II structures (HLA-DR1, PDB:3L6F; HLA-DP2, PDB: 3LQZ; 907 
HLA-DQ6, PDB: 1UVQ; I-Ab, PDB: 1LNU; I-Ek, PDB: 1R5V) available in PDB were 908 
retrieved and superposed based on the α1 and β1 domains shown in helices and loops 909 
with different colors. The conserved Arg residues at the C-terminus of the peptide 910 
binding groove which are comparable to the Arg83 of BF2*1201 are shown in sticks. 911 
The MHC II-presented peptides with extended residues out of the grove were shown in 912 
ribbons with corresponding colors. C. The superposition of the five MHC II structures 913 
(shown in green) with BF2*1201/S1 (yellow), BF2*1201/A6 (cyan) and 914 
HLA-A*0201/Mn2 (purple, PDB: 3I6G). C. The superposition of BF2*1201/S1, 915 
BF2*1201/A6, HLA-A*0201/Mn2 (PDB: 3I6G) with other chicken MHC I molecules 916 
(BF2*0101, PDB: 4D0D; BF2*0401, PDB: 4E0R; BF2*1401, PDB: 4CW1; 917 
BF2*2101, PDB: 3BEW);. 918 
E-I. Detailed C terminal anchoring mode of the five representative MHC II-presented 919 
peptides. 920 
 921 
